Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

Fichtner‐Feigl, Stefan

doi:10.1002/ags3.12454

Cited by 6 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations in exon 2 were found to increase the risk of recurrence two-fold over the wild-type, and these findings are consistent with those of other reports (9,18,19).…”

Section: Discussionsupporting

confidence: 91%

Prognostic Value ofKRASExon-specific Mutations in Patients With Colorectal Cancer

et al. 2023

View full text Add to dashboard Cite

Background/Aim: The clinical significance of many RAS-family mutations in colorectal cancer (CRC) remains unclear. The purpose of this study was to investigate the relationship of RAS mutations on an exon basis (i.e., mutations in KRAS exons 2,3, and 4 and in NRAS) with clinicopathological features and prognosis in CRC. Patients and Methods: We performed a retrospective cohort study of the medical records and frozen tissue samples of 268 consecutive patients with stage I-III CRC who underwent curative resection at a single institution between 2014 and 2018. Results: The RAS mutation rate was significantly associated with age and histology. Patients with KRAS exon 2 mutations exhibited shorter recurrence-free survival compared to those with KRAS wild-type, KRAS exon 3 mutations, KRAS exon 4 mutations, and NRAS mutations (73.0% vs. 85.5%, 86.7%, 85.7%; p=0.031). Age and histology were independent risk factors for RAS mutations. RAS mutations were independent prognostic factors with respect to recurrence-free survival in patients with stage I-III CRC. Conclusion: In stage I-III CRC patients, KRAS exon 2 mutations had the worst prognosis, whereas KRAS wild type, exon 3 mutations, exon 4 mutations, and NRAS mutations had better prognoses. Patients and MethodsPatient selection. We retrospectively analyzed 286 consecutive patients with CRC who underwent curative resection at Teikyo University Hospital, Japan, from 2015 through 2018. This study included patients identified as having pathological stages I-III CRC according to the 8 th edition of the American Joint Committee on Cancer (AJCC) staging system (7).

show abstract

“…Mutations in exon 2 were found to increase the risk of recurrence two-fold over the wild-type, and these findings are consistent with those of other reports (9,18,19).…”

Section: Discussionsupporting

confidence: 91%

Prognostic Value ofKRASExon-specific Mutations in Patients With Colorectal Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Mutations in exon 2 were found to increase the risk of recurrence twofold over wild-type, and these ndings are consistent with those of other reports. (9) (19) (20).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of KRAS exon 2, exon 3 and exon 4 mutations in colorectal cancer patients

Asako

Hayama

Hashiguchi

et al. 2022

Preprint

View full text Add to dashboard Cite

The clinical significance of many RAS-family mutations in colorectal cancer (CRC) remains unclear. The purpose of this study was to investigate the relationship of mutations on an exon basis (i.e., mutations in KRAS exons 2, 3 and 4 and in NRAS) with clinicopathological features and prognosis in CRC. We performed a retrospective cohort study of the medical records and frozen tissue samples of 268 consecutive patients with stage I-III CRC who underwent curative resection at a single institution in 2014–2018. The RAS mutation rate was significantly associated with age and histology. Patients with KRAS exon 2 mutations exhibited shorter RFS compared to those with KRAS wild-type, KRAS exon 3 mutations, KRAS exon 4 mutations and NRAS mutations (73.0% vs. 85.5%, 86.7%, 85.7%. p = 0.031). Age and histology were independent risk factors for RAS mutations. RAS mutations were independent prognostic factors with respect to RFS in patients with stage I–III CRC. In stage I–III CRC patients, KRAS exon 2 mutations have the worst prognosis, while RAS wild type, RAS exon 3 mutations, RAS exon 4 mutations and NRAS mutations have better prognoses.

show abstract

Impact of perioperative prognostic nutritional index changes on the survival of patients with stage II/III colorectal cancer

Tatsuta,

Sakata,

Kojima

et al. 2024

Annals of Gastroent Surgery

View full text Add to dashboard Cite

AimTo assess the impact of perioperative prognostic nutritional index (PNI) changes on prognosis and recurrence after colorectal cancer surgery.MethodsA total of 475 patients who underwent curative resection for primary colorectal adenocarcinoma and were diagnosed with pathological stage (pStage) II/III were retrospectively reviewed. The patients were divided into two groups: the high group (preoperative PNI ≤ postoperative PNI, n = 290) and the low group (preoperative PNI > postoperative PNI, n = 185).ResultsThe low group exhibited significantly higher recurrence and mortality rates (all p < 0.001). Kaplan–Meier analysis showed worse overall and recurrence‐free survival in the low group (all p < 0.001). Perioperative PNI changes predicted prognosis and recurrence independent of preoperative nutritional conditions. Subgroup analyses showed better overall survival and recurrence‐free survival in the high group across various parameters, such as patient background, surgical outcomes, adjuvant chemotherapy, and pathological characteristics. Multivariate analysis revealed that the low group based on perioperative PNI changes (hazard ratio [HR]: 5.809, 95% confidence interval [CI]: 3.451–9.779, p < 0.001), pathological T stage (HR: 1.962, 95% CI: 1.184–3.253, p = 0.009), and pathological N stage (HR: 3.434, 95% CI: 1.964–6.004, p < 0.001) were identified as independent predictors of worse overall survival.ConclusionsPatients with pStage II/III colorectal cancer who demonstrate a lower postoperative PNI levels compared to preoperative had poorer overall survival and recurrence‐free survival. Perioperative PNI changes can serve as useful biomarkers for predicting survival and recurrence.

show abstract

Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

Cited by 6 publications

References 46 publications

Prognostic Value ofKRASExon-specific Mutations in Patients With Colorectal Cancer

Prognostic Value ofKRASExon-specific Mutations in Patients With Colorectal Cancer

Prognostic value of KRAS exon 2, exon 3 and exon 4 mutations in colorectal cancer patients

Impact of perioperative prognostic nutritional index changes on the survival of patients with stage II/III colorectal cancer

Contact Info

Product

Resources

About